Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
about
Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismAnticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.Quantitative measurement of heparin in comparison with conventional anticoagulation monitoring and the risk of thrombotic events in adults on extracorporeal membrane oxygenation.Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.Heparin sensing and binding - taking supramolecular chemistry towards clinical applications.A guide to the use of anticoagulant drugs in children.Anticoagulation strategies and difficulties in neonatal and paediatric extracorporeal membrane oxygenation (ECMO).Management of systemic unfractionated heparin anticoagulation during therapeutic plasma exchange.Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques.Thromboelastographic monitoring of the effect of unfractionated heparin in healthy dogs.How We Manage Pediatric Deep Venous Thrombosis.Evaluation of safety and effectiveness of standardized antifactor Xa-based unfractionated heparin protocols in obese versus non-obese patients.Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support.Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.Prothrombotic State in a Patient With Acute Liver Failure: The Question of Anticoagulation.Protocolled Redefinition of the Therapeutic Range for Unfractionated Heparin: Lost in Translation?Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms.Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions.Pyrene-based heparin sensors in competitive aqueous media – the role of self-assembled multivalency (SAMul)
P2860
Q26992262-A7EC1BD9-6582-425A-A650-95D2F36D66A2Q28079081-B3D5E6D5-4299-4A38-B614-5B63D7C7338AQ33409966-5A1BC629-34EF-474D-BB98-70131622319EQ36076171-C87DBA25-F6FF-4EB9-80AA-80EE72191FFAQ37318663-AB13872A-AAF6-441B-89B3-646C9B3066B9Q38135753-489A2A9B-2601-425E-A007-B6C8592ADD17Q38364859-4E9A7126-A9E2-4774-8FA1-2DD978A4F2A5Q38523207-B5C03BEC-6BBB-497F-9987-E2D3E945E68CQ38692312-F2A72C6C-EFEB-4606-B51B-B8F2ED16AE13Q38807522-F0F9E6F7-C591-4194-906E-C33F47E0D175Q38812360-360C65A0-A52D-4696-8772-2E237FABFEE9Q38926114-73C3FF77-B15C-4446-A80E-9AF90D1AE22BQ39030017-111C933F-7986-4EE1-BBFF-C727C38BE83DQ39457136-315AE50C-C090-4DA4-A3FF-5E75DF12D9EDQ43853631-BF254EA8-417B-45E5-B095-547C44CBEAD5Q44315763-B3670266-EA3F-4BC0-BAAF-D07BB3436566Q46197690-219530D6-7924-43C0-8CE1-49076EB141E4Q47571298-E2A98724-BE3E-4DA2-8CFD-B1A6383A6369Q48738998-A83603E5-2794-4A06-9629-6C6A2CDCA888Q50047585-B1F18CDE-EC9B-410D-82C3-3055AB5CAB65Q55337905-2ACC95FE-55F6-4612-8109-58C4D5366047Q58324564-B3334F91-BB07-4AD4-8EB2-E43895D98831
P2860
Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antifactor Xa levels versus ac ...... toring unfractionated heparin.
@en
type
label
Antifactor Xa levels versus ac ...... toring unfractionated heparin.
@en
prefLabel
Antifactor Xa levels versus ac ...... toring unfractionated heparin.
@en
P2860
P1433
P1476
Antifactor Xa levels versus ac ...... toring unfractionated heparin.
@en
P2093
Jeremy W Vandiver
Thomas G Vondracek
P2860
P304
P356
10.1002/J.1875-9114.2011.01049.X
P407
P577
2012-04-24T00:00:00Z